As Indonesia’s state-owned pharmaceutical holding, PT Bio Farma (Persero) was founded with a meaningful mission: to improve public health through innovation in biotechnology and vaccine production. Founded in 1890, Bio Farma plays a crucial role not just for Indonesia, but also for the global health community, in doing so by creating affordable, high-quality vaccines to fight infectious diseases and improve the well-being of millions of people around the world. In order to create an excellent pharmaceutical industry ecosystem in Indonesia, Bio Farma was appointed to become the parent entity, which consists of PT Kimia Farma Tbk, PT Indofarma Tbk, and PT Industri Nuklir Indonesia (INUKI).

With its great production capacity and WHO pre-qualification status, Bio Farma export vaccines to more than 160 countries and ensured that all people including those in other low and middle-income countries had access to safe and effective vaccines. Listed on top five WHO suppliers, Bio Farma produce 3,1 billion dosage vaccines and in 2023 more than 2 billion dosages were distributed globally. Export value of Bio
Farma has grown 80% in the past 2 years. When the COVID-19 pandemic spread worldwide, Bio Farma also rose to the challenge. As Southeast Asia's largest vaccine producer, Bio Farma played a key role in supporting both national and global efforts to combat the virus. Bio Farma became a key partner in producing and distributing COVID-19 vaccines, including the Sinovac vaccine under the brand name
CoronaVac.

What’s New?
One of Bio Farma’s proudest achievements was the development of IndoVac, Indonesia’s first domestically produced COVID-19 vaccine. Launched in 2022, IndoVac was created through a technology transfer partnership with Baylor College of Medicine, PATH and WHO. It’s a halal-certified, protein subunit vaccine designed for safety, affordability, and global access. Recently, Bio Farma has developed vaccine nOPV2 in
collaboration with Bill & Melinda Gates Foundation and UNICEF. Bio Farma also expanded the implementation of SMDV (Sistem Manajemen Distribusi Vaksin) or MedTrack as the first system in the world applied to the COVID-19 vaccine, where this system will monitor and
continuously update the truck’s position and vaccine’s temperature which reported to the Command Center at Bio Farma’s head office. In the future, this SMDV can be applied to all pharmaceuticals, so there will be no more incidents of fake vaccines or unregistered pharmaceutical products on the market in near future.

With a strong focus on research and development, Bio Farma continues to innovate in the field of biotechnology, diagnostics, and biopharmaceuticals. Bio Farma is now investing in pandemic preparedness, vaccine research, and biotech innovations to help the world be ready for future health threats. With over a century of experience and a future-focused mindset, PT Bio Farma continues to lead in health innovation, supporting both national health resilience and global health security.